Oxford Nanopore Technologies, Inc.

Oxford Nanopore Technologies Inc., a foreign-owned biotechnology company based in New York, supplies next-generation genomic sequencing instruments, consumables, and reagents to federal research agencies as a prime contractor exclusively—the company holds no subcontract roles in the federal footprint. All 391 awards in the recent portfolio are prime purchases across civilian research and health agencies with no set-aside designations; Oxford Nanopore competes full-and-open and does not pursue small-business or disadvantaged-business set-asides.

The vendor's federal work centers on three concrete product lines. First, sequencing platforms: the GridION MK1 and PromethION series (solo, 24, 48-channel) instruments that perform real-time, long-read DNA and RNA analysis. Second, consumables: flow cell packs (R9.4.1, R10.4.1 variants), ligation sequencing kits, rapid barcoding kits, and library preparation reagents compatible with Oxford Nanopore equipment. Third, software and warranty: one-year and multi-year licenses, device warranties, and maintenance agreements for deployed instruments. Representative awards include a June 2026 purchase order from the National Institute on Aging valued at $599,755 for long-read RNA sequencing kits supporting postmortem brain sample analysis under the Induced Pluripotent Stem Cell Neurodegenerative Disease Initiative; a September 2024 FDA award of $295,137 for a 12-month PromethION 2 Solo lease with consumables through November 2028; and a May 2023 USDA award of $560,905 for sequencing systems supporting veterinary diagnostic work.

Customer concentration is dispersed across civilian health and agricultural research. The top five funding agencies account for 45% of award count: CDC Pittsburgh (62 awards, $2 million), National Human Genome Research Institute (37 awards, $1.3 million), USDA Agricultural Research Service (30 awards, $1.4 million), National Institute on Aging (27 awards, $2.8 million), and FDA (21 awards, $1.4 million). By potential value, the National Institute on Neurological Disorders and Stroke anchors the top tier with six awards carrying $4.1 million combined potential value, while NIA, CDC Pittsburgh, USDA, and FDA follow. No single customer dominates; Oxford Nanopore serves 51 distinct federal agencies. Recent trajectory shows declining award volume year over year (54 awards in 2022 to eight through mid-2026), with 17 awards (combined potential value $2.4 million) completing within the next twenty-four months and facing recompete exposure.

Oxford Nanopore holds three parent vehicles. A $325,000 Blanket Purchase Agreement with the Defense Health Agency (February 2024, running through February 2029) funds reagents, equipment, warranty, and license services; a $740,000 Indefinite Delivery Contract with USDA's Animal and Plant Health Inspection Service (September 2024, through August 2029) covers genomic sequencing consumables; and a $66,990 BPA with HHS Office of Acquisitions and Grants (September 2024, through September 2028) sources MinION consumables and reagents. The BPA and IDC vehicles show consistent task-order activity but modest utilization relative to ceiling.

Oxford Nanopore's federal footprint is dominated by PSC 6550 (Laboratory Equipment and Supplies, 237 awards) and NAICS 325413 (Analytical Laboratory Instrument Manufacturing, 230 awards), reflecting its role as a life-sciences instrumentation vendor rather than a service integrator or systems contractor. The vendor operates exclusively through direct purchase orders and small BPA calls rather than through large government-wide vehicles or agency IDIQs, positioning it as a specialized consumables and equipment supplier with narrow competitive exposure to integrators seeking sequencing as a component capability.